PURE Bioscience, Inc. (PURE)
OTCMKTS: PURE · Delayed Price · USD
0.0750
+0.0001 (0.13%)
Jun 20, 2024, 10:30 AM EDT - Market closed

PURE Bioscience Income Statement

Millions USD. Fiscal year is Aug - Jul.
Year
20232022202120202019 2018 - 1996
Revenue
1.881.853.936.921.91
Upgrade
Revenue Growth (YoY)
1.30%-52.81%-43.23%262.34%7.61%
Upgrade
Cost of Revenue
0.910.851.852.90.73
Upgrade
Gross Profit
0.9712.084.021.18
Upgrade
Selling, General & Admin
4.34.114.053.76.42
Upgrade
Research & Development
0.30.320.340.320.35
Upgrade
Other Operating Expenses
-00-00.010
Upgrade
Operating Expenses
4.64.434.394.026.77
Upgrade
Operating Income
-3.94-3.43-2.310.01-5.59
Upgrade
Interest Income
0.010.0100.010.01
Upgrade
Interest Expense
0.010.0100.010.01
Upgrade
Other Expense / Income
0.010.070.010.010.97
Upgrade
Pretax Income
-3.96-3.49-2.320-6.55
Upgrade
Income Tax
0.010.0100.010.01
Upgrade
Net Income
-3.96-3.5-2.32-0.01-6.56
Upgrade
Shares Outstanding (Basic)
11189878273
Upgrade
Shares Outstanding (Diluted)
11189878573
Upgrade
Shares Change
25.41%1.91%3.03%16.10%8.33%
Upgrade
EPS (Basic)
-0.04-0.04-0.03-0.00-0.09
Upgrade
EPS (Diluted)
-0.04-0.04-0.03-0.00-0.09
Upgrade
Free Cash Flow
-3.31-2.5-1.690.61-3
Upgrade
Free Cash Flow Per Share
-0.03-0.03-0.020.01-0.04
Upgrade
Gross Margin
51.73%53.97%52.84%58.13%61.86%
Upgrade
Operating Margin
-210.07%-184.84%-58.85%0.13%-292.77%
Upgrade
Profit Margin
-211.03%-188.72%-59.05%-0.09%-343.69%
Upgrade
Free Cash Flow Margin
-176.40%-134.86%-42.98%8.83%-157.31%
Upgrade
Effective Tax Rate
---250.00%-
Upgrade
EBITDA
-3.52-3.21-2.140.2-5.35
Upgrade
EBITDA Margin
-187.27%-173.34%-54.57%2.91%-280.09%
Upgrade
Depreciation & Amortization
0.120.210.170.190.24
Upgrade
EBIT
-3.63-3.43-2.320.01-5.59
Upgrade
EBIT Margin
-193.50%-184.84%-58.95%0.13%-292.72%
Upgrade
Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.